Mirikizumab Shows Promise for Moderate to Severe Crohn’s

WASHINGTON, DC — The selective interleukin (IL)–23p29 monoclonal antibody mirikizumab demonstrated safety and efficacy in people with moderate to severe Crohn’s disease compared with placebo up to 52 weeks, according to results of the phase 3 randomized, double blind, treat-through VIVID-1 study.  Bruce E. Sands, MD…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button